Jardiance < sup > ® < /sup > demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulphonylurea in adults with Type 2 Diabetes
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Phase III data show investigational compound empagliflozin reduced blood glucose in adults with Type 2 Diabetes treated with basal insulin
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Jardiance < sup > ® < /sup > (empagliflozin) to be studied for the treatment of people with chronic heart failure
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
New Jardiance < sup > ® < /sup > (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Pooled analysis data showed improvements in glycaemic parameters, body weight and blood pressure with investigational agent empagliflozin in adults with Type 2 Diabetes
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Boehringer Ingelheim and Eli Lilly and Company present efficacy and safety data on linagliptin and investigational compound, empagliflozin in various diabetes subpopulations
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Jardiance < sup > ® < /sup > is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Type 2 diabetes: Synjardy < sup > ® < /sup > (empagliflozin/metformin hydrochloride) approved in the European Union
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Type 2 Diabetes: Investigational empagliflozin/linagliptin combination tablet shows sustained reduction in blood glucose in Phase III study
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Type 2 diabetes: CHMP recommends empagliflozin/metformin hydrochloride for approval in the European Union
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Type 2 Diabetes: Jardiance < sup > ® < /sup > (empagliflozin) as an add-on therapy significantly reduced blood glucose and body weight in two newly presented Phase III trials
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Type 2 Diabetes: European Commission approves Jardiance < sup > ® < /sup > (empagliflozin)
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Phase III data show significant reductions in blood glucose with investigational compound empagliflozin used as monotherapy in adults with Type 2 Diabetes
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
